Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Vistagen Therapeutics (VTGN) over the last 13 years, with Q4 2025 value amounting to $47.4 million.

  • Vistagen Therapeutics' Cash & Equivalents fell 3659.77% to $47.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $47.4 million, marking a year-over-year decrease of 3659.77%. This contributed to the annual value of $67.1 million for FY2025, which is 4366.6% down from last year.
  • Vistagen Therapeutics' Cash & Equivalents amounted to $47.4 million in Q4 2025, which was down 3659.77% from $62.8 million recorded in Q3 2025.
  • Over the past 5 years, Vistagen Therapeutics' Cash & Equivalents peaked at $126.6 million during Q4 2023, and registered a low of $9.6 million during Q2 2023.
  • Its 5-year average for Cash & Equivalents is $67.8 million, with a median of $67.6 million in 2022.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first surged by 750890.71% in 2021, then crashed by 8149.56% in 2023.
  • Over the past 5 years, Vistagen Therapeutics' Cash & Equivalents (Quarter) stood at $83.7 million in 2021, then crashed by 70.09% to $25.0 million in 2022, then soared by 405.65% to $126.6 million in 2023, then tumbled by 40.98% to $74.7 million in 2024, then tumbled by 36.6% to $47.4 million in 2025.
  • Its Cash & Equivalents was $47.4 million in Q4 2025, compared to $62.8 million in Q3 2025 and $49.0 million in Q2 2025.